Iolyx Therapeutics
Iolyx Therapeutics is transforming the standard of care for ocular disease at the intersection of immunology and ophthalmology. They develop targeted therapeutics to treat ocular inflammation with a focus on safety, efficacy, and convenience, aiming to improve treatments for diseases affecting the front and back of the eye.
Industries
Nr. of Employees
small (1-50)
Iolyx Therapeutics
Patents
Products
Clinical-stage immunomodulatory therapeutic for autoimmune dry eye
A clinical-stage therapy designed to modulate ocular inflammation for autoimmune dry eye, with reported Phase II clinical results.
Pipeline of therapies for anterior and posterior ocular inflammatory diseases
Multiple development-stage programs targeting front-of-eye conditions (e.g., dry eye, ocular allergy, rosacea, anterior uveitis) and back-of-eye conditions (e.g., posterior uveitis, diabetic retinopathy, age-related macular degeneration).
Clinical-stage immunomodulatory therapeutic for autoimmune dry eye
A clinical-stage therapy designed to modulate ocular inflammation for autoimmune dry eye, with reported Phase II clinical results.
Pipeline of therapies for anterior and posterior ocular inflammatory diseases
Multiple development-stage programs targeting front-of-eye conditions (e.g., dry eye, ocular allergy, rosacea, anterior uveitis) and back-of-eye conditions (e.g., posterior uveitis, diabetic retinopathy, age-related macular degeneration).
Services
Design and conduct of clinical trials for ocular therapeutics, demonstrated by progression to and reporting of Phase II clinical results.
Non-clinical study design and execution supporting safety and pharmacology assessment of ocular candidates prior to clinical entry.
Design and conduct of clinical trials for ocular therapeutics, demonstrated by progression to and reporting of Phase II clinical results.
Non-clinical study design and execution supporting safety and pharmacology assessment of ocular candidates prior to clinical entry.
Expertise Areas
- Immuno-ophthalmology
- Ocular drug delivery and formulation
- Preclinical pharmacology and toxicology for ocular therapies
- Clinical development of ophthalmic therapeutics (Phase II experience)
Key Technologies
- Targeted ocular drug delivery systems
- Formulation science and CMC scale-up
- Preclinical ocular pharmacology models
- Toxicology assessment for ocular therapeutics